In addition, several markers have been widely used to predict a BC prognosis in clinical practice, such as the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (Her2) status, as well as several clinicopathologic features, such as tumor size, histologic grade, and lymph node involvement [7, 8]. The gene discussed is ERBB2; the disease is neoplasm.